Table 2 Characteristics of included studies: baseline characteristics systematic reviews of randomized controlled trials.
Characteristics Among women with PCOS Among women with clomiphene resistant PCOS Salehpour et al. 2009 [17 ] Gayatri et al. 2010 [28 ] Oner and Muderris 2011 [18 ] Salehpour et al. 2012 [19 ] Rizk et al. 2005 [20 ] Elnashar et al. 2007 [14 ] Hashim et al. 2010 [21 ] Nasr 2010 [22 ] NAC/placebo NAC/metformin NAC/metformin NAC/placebo NAC/placebo NAC/metformin NAC/metformin NAC/placebo Total randomized, 46 115 100 180 153 64 192 60 Randomised, 46 56/59 50 /50 90/90 NA 32/32 95/97 30/30 Completed, 36 50/50 45/31 82/85 75/75 30/31 97/95 30/30 Total, 36 100 76 167 150 61 192 60 Attrition rate 21.7% 13% 24% 7% 2% 4.7% 0% 0% Baseline Characteristics Age, years 27.2 (5.4) 22.6 (3.8); 23.7 (4.4); 27.22 (3.32); 28.9 (4.7); 27.33 (3.35); 27.3 (2.6); 28.4 (4.2); Weight, kg 74.1 (11.7) 70.5 (3.45); NA NA 101.3 (12.4); NA NA NA BMI, kg/m2 29.5 (4.1) 26.54 (2.35); 23 (4.6); 26.78 (2.24); 30.5 (2.6); 25.8 (0.94); 26.6 (2.2); 28.6 (3.7); Amenorrhea patients (%) 2 (11.1%) 4 (8%); NA NA NA NA 6 (6.3%); 5 (17%); Oligomenorrhea, NA 29 (58%); NA NA NA 76.7 (23); 89 (93.7%); NA Hirsutism, 11 (61.1%) 2 (4%); NA NA NA NA NA 16 (53%); Acne, 5 (27.8%) 1 (2); 2 (4) NA NA NA NA NA NA Duration of Infertility, mean (SD) 4.5 (2.2) 10 (20); NA 4.39 (1.96); 5 (2.9); NA 4.5 (1.2); 5.3 (1.9); Testosterone level, nmol/dL, mean (SD) 0.91 (0.48) 1.55 (0.29); 80.8 (41.1); NA NA 98.27 (31.5); 1.06 (0.27); NA FPG, mg/dL, mean (SD) 95.6 (10.9) 88.53 (5.14); 88.5 (6.8); NA 81.9 (12.6); 83.3 (8.8); 91.3 (1.5); NA HOMA-IR 5.22 (5.58); 5.52 (1.35); 4.5 (1.2); NA NA NA NA NA
